Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide.
Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19.
In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications.
The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International.
Further, it sells Captisol materials.
Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 24 | 1.40 Decreased by -1.41% | 1.06 Increased by +32.08% |
| May 7, 24 | 1.20 Decreased by -47.37% | 0.78 Increased by +53.85% |
| Feb 27, 24 | 1.38 Increased by +1.47% | 0.66 Increased by +109.09% |
| Nov 8, 23 | 1.02 Decreased by -22.14% | 0.61 Increased by +67.21% |
| Aug 8, 23 | 1.42 Increased by +37.86% | 0.64 Increased by +121.87% |
| May 4, 23 | 2.28 Increased by +293.10% | 0.89 Increased by +156.18% |
| Feb 22, 23 | 1.36 Decreased by -24.44% | 1.19 Increased by +14.29% |
| Nov 7, 22 | 1.31 Decreased by -17.09% | 0.43 Increased by +204.65% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 51.81 M Increased by +57.64% | -7.17 M Increased by +43.93% | Decreased by -13.84% Increased by +64.43% |
| Jun 30, 24 | 41.53 M Increased by +57.52% | -51.91 M Decreased by -2.37 K% | Decreased by -124.99% Decreased by -1.54 K% |
| Mar 31, 24 | 30.98 M Decreased by -29.56% | 86.14 M Increased by +105.34% | Increased by +278.07% Increased by +191.52% |
| Dec 31, 23 | 28.10 M Decreased by -44.22% | 18.19 M Increased by +225.14% | Increased by +64.72% Increased by +324.36% |
| Sep 30, 23 | 32.87 M Decreased by -50.27% | -12.79 M Decreased by -3.27 K% | Decreased by -38.92% Decreased by -6.47 K% |
| Jun 30, 23 | 26.37 M Decreased by -54.08% | 2.29 M Increased by +355.87% | Increased by +8.69% Increased by +657.22% |
| Mar 31, 23 | 43.98 M Decreased by -3.75% | 41.95 M Increased by +372.66% | Increased by +95.38% Increased by +383.29% |
| Dec 31, 22 | 50.38 M Decreased by -30.48% | -14.53 M Decreased by -192.55% | Decreased by -28.85% Decreased by -320.83% |